Plants can be used to study how and why people respond differently to drugsSeptember 27, 2007RIVERSIDE, Calif. - While prescription medications work successfully to cure an ailment in some people, in others the same dose of the same drug can cause an adverse reaction or no response at all. According to a research team led by Sean Cutler, an assistant professor of plant cell biology at UC Riverside, such variation in drug responses can be analyzed by studying much simpler organisms - like plants. "The genetics behind variable drug responses is not peculiar to humans but exists also in other branches on the tree of life," Cutler said. "We can harness simple organisms to understand more about the genetics and biochemistry of variable drug responses, which could help uncover new factors that contribute to variable drug responses in humans." Study results appear in the Sept. 23 online publication of Nature Chemical Biology. Focusing on Arabidopsis thaliana, a weedy plant in the mustard family, Cutler's lab discovered a key protein in the plant that creates drug resistance. Called UGT (UDP-glycosyltransferase), the protein is a member of a family of proteins that also affect drug sensitivity in humans. "Similar biochemical processes are affecting drug sensitivity in both plants and animals," said Cutler, who joined UCR's Department of Botany and Plant Sciences and the Center for Plant Cell Biology in January 2007. "These similarities suggest that plants can be useful for studying problems of human interest like drug responses." In their research, Cutler and his research team first screened and tested thousands of drug-like compounds in the lab as they searched for new inhibitors of plant growth. In the process, they discovered a new molecule, called hypostatin, which acts like a drug in inhibiting plant growth in some Arabidopsis plants. At the same time, the researchers grew Arabidopsis plants in a solution containing hypostatin, which allowed the plant cells to take up hypostatin. Cutler and his team found that the plants' UGT activates hypostatin by adding a sugar molecule to it. They also found that in plants that had a genetically defective UGT, hypostatin did not work properly because no sugar molecules - necessary for activating hypostatin - were added to it; in such plants, therefore, growth was not affected. "This mechanism is very similar to that seen in humans, where altered drug sensitivity can occur because of defective or atypical sugar-tagging proteins," Cutler said. His lab made the discovery as part of its ongoing research aimed at identifying and characterizing new bioactive compounds in plants. Next in their research, Cutler and his colleagues plan to expand their search for other sugar-activated molecules, like hypostatin. University of California - Riverside |
|||||||||||||||||||||
| Related Drug Response Current Events and Drug Response News Articles New cancer drug test promises safer and more effective clinical trials A group of scientists from Hamburg may have taken a big step towards more effective cancer drug development. Inherited risk factors increase odds of developing childhood acute lymphoblastic leukemia Scientists at St. Jude Children's Research Hospital have identified inherited variations in two genes that account for 37 percent of childhood acute lymphoblastic leukemia (ALL), including a gene that may help predict drug response. A crystal ball for brain cancer? UCLA researchers have uncovered a new way to scan brain tumors and predict which ones will be shrunk by the drug Avastin -- before the patient ever starts treatment. New 3-D structural model of critical H1N1 protein developed In just two weeks from the time the first patient virus samples were made available, Singapore scientists report an evolutionary analysis of a critical protein produced by the 2009 H1N1 influenza A virus strain. Tumor growth and chemo response may be predicted by mathematical model The aggressiveness of tumors and their susceptibility to chemotherapy may become easier to predict based on a mathematical model developed at The University of Texas Health Science Center at Houston. Are we cherry picking participants for studies of antidepressants? Findings from clinical studies used to gain Food and Drug Administration approval of common antidepressants are not applicable to most patients with depression, according to a report led by the University of Pittsburgh Graduate School of Public Health. CSHL team develops mouse models of leukemia that predict response to chemotherapy Being able to accurately predict how a given cancer will respond to chemotherapy would spare patients with non-responsive tumors the burden of undergoing toxic and ultimately unhelpful treatment. Just as important, knowing which of a patient's cancer-causing genetic lesions are contributing to drug resistance might help doctors redesign therapy for maximum benefit. Antidepressants in suicide prevention Antidepressants are the cornerstone of treatment of depressive disorders in health care. Their efficacy in treating depression is undisputable, although it leaves room for improvement. Environmental enrichment can reduce cocaine use, researchers find Simple environmental enrichment and increased social stress can both affect the level of individual drug use, according to new monkey research at Wake Forest University School of Medicine. Johns Hopkins to participate in 1000 Genomes Project Researchers at the McKusick-Nathans Institute of Genetic Medicine (IGM) at Johns Hopkins will join other national and international scientists in the 1000 Genomes Project, an ambitious effort that will involve sequencing the genomes of numerous people from around the world to create the most detailed and medically useful picture to date of human genetic variation. More Drug Response Current Events and Drug Response News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||